Type II IFN (IFNγ) treatment can cause cell cycle arrest and inhibit the growth of pancreatic cancer cells by triggering caspase-1- and IRF1-dependent apoptosis (Detjen et al., 2001). The gene discussed is CASP1; the disease is familial pancreatic carcinoma.